<!DOCTYPE html>
<html lang="ru">

<head>
  <meta charset="utf-8">

  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">

  <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.5.0/css/all.css">
  <link href="https://fonts.googleapis.com/css?family=Open+Sans" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Germania+One" rel="stylesheet">
  <link rel="stylesheet" href="css/main.min.css">
  <title>Tegretol300x250</title>
</head>

<body>

  <div class="container300x50">
    <img class='Vector_Smart_Object222_copy_6' src="img/300x50/Vector_Smart_Object222_copy_6.png"
      alt="Vector_Smart_Object222_copy_6">
    <h2 class="Your_epilepsy">Your epilepsy patients could achieve seizure freedom with
      <br>Tegretol<sup>&#174;1</sup>
      or Trileptal<sup>&#174;2</sup> at any age</h2>

    <div class="falily">
      <img src="img/300x50/GettyImages-878493416.png" alt="GettyImages">
    </div>








    <div class="footer">

      <div class=''>
        <img class='' src="img/300x50/Novartis_Logo.png" alt="Novartis_Logo">
      </div>

      <div class='footer_div'>
        <div class='a_footer'>
          <a href="#">Rollover to learn more</a>
          <a href="#" class="p_Global_Basic">Global Basic Succinct Statement</a>
        </div>

        <div class='p_footer'>
          <p>&#169; 2019 Novartis</p>
          <p>10/19</p>
          <p>GLEM/TRILEPTAL/0023</p>
        </div>
      </div>
      <div class="two_baners">
        <img src="img/300x50/Tegretol.png" alt="Tegretol">

        <img src="img/300x50/Trileptal.png" alt="Trileptal">
      </div>
      <div class='pp_footer'>
        <p><b>1. Glauser T, <i>et al. Epilepsia</i> 2013; 54(3): 551-63. doi: 10.1111/epi.12074; &#160; &#160;
          &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;
          2. Kanner AM, <i>et al. Neurology</i> 2018; 91(2): 74-81.</b></p>
      </div>
    </div>
  </div>

















  <div class="big_banner728x540">
    <img class="Vector_Smart_Object22" src="img/Vector_Smart_Object22_copy_56.png" alt="Vector_Smart_Object22_copy_5">
    <div class="family">
      <img src="img/GettyImages-8784934162.png" alt="GettyImages">
    </div>

    <div class="big_banner728x540_text">
      <h2 class="Did_you_know">Did you know that seizure worry is the most important concern for patients with
        epilepsy?<sup>1</sup></h2>

      <div class="nuwly_percent">
        <div class="nuwly_percent_p1">
          <h1>72.2%</h1>
          <p class='n_39'>(n=39/54)</p>
          <p>of newly-diagnosed epilepsy patients (â‰¥17 years) achieved 1-year seizure freedom
            with<br><span>Trileptal<sup>&#174;</sup> (oxcarbazepine) </span>monotherapy<sup>*2</sup></p>
        </div>
        <div class="nuwly_percent_p1">
          <h1>61%</h1>
          <p class='n_39'>(n=49/81)</p>
          <p>of newly-diagnosed paediatric patients (5-18 years) achieved seizure freedom at 48 weeks
            with<span>Trileptal<sup>&#174;</sup> (oxcarbazepine) </span>monotherapy<sup>**3</sup></p>
        </div>
      </div>
      <div class="z_i">
        <h3 class="across">Across 46 randomised clinical trials,</h3>
        <p class="across_p1"><span>Tegretol<sup>&#174;</sup> (carbamazepine)</span> showed superior efficacy
          compared to many other
          anti-epileptic drugs in newly-diagnosed paediatric patients with focal epilepsy<sup>4</sup></p>
        <p class="across_p2">
          <span>Tegretol<sup>&#174;</sup> (carbamazepine)</span> is also a suitable first-line treatment for
          adults with partial onset seizures<sup>5</sup>
        </p>
      </div>
      <div class="text_ul">
        <p>
          <b>1. Chen J, <i>et al. Epilepsy Behav</i> 2018; 82: 128-32; 2. Pauletto G and
            Bergonzi P. <i>Seizure</i> 2006; 15(3): 150-5;<br>
            3. Guerreiro MM, <i>et al. Epilepsy Res</i> 1997; 27(3): 205-13; 4. Rosati A,
            <i>et al.
              Epilepsia</i> 2018; 59(2): 297-314;<br> 5. NICE. Epilepsies: diagnosis and
            management, Clinical Guideline
            137.
          </b>
        </p>
      </div>
    </div>

    <div class="footer">
      <img class='' src="img/Novartis_Logo2.png" alt="Novartis_Logo"><img class='' src="img/Tegretol2.png"
        alt="Tegretol"><img class='' src="img/Trileptal2.png" alt="Trileptal">
      <div class="">
        <a href="#" class="p_Global_Basic">Global Basic Succinct Statement</a>
        <span>10/19</span>
        <span>GLEM/TRILEPTAL/0023</span>
      </div>
    </div>

  </div>






  <script src="js/scripts.min.js"></script>

</body>

</html>